Publications by authors named "Elke Heitmann"

Claim this Profile
T
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.
Annabel Barrett, Kristina S Boye, Luis-Emilio García-Pérez, Francesco Giorgino, Bruno Guerci, Elke Heitmann

J Med Econ· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
Francesco Giorgino, Bruno Guerci, Martin Füchtenbusch, Jérémie Lebrec, Kristina Boye, Elke Heitmann

Diabetes Obes Metab· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Kristina S Boye, Jérémie Lebrec, Anne Dib, Elke Heitmann, Marco Orsini Federici

Diabetes Obes Metab· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.
Heike Jung, Sascha R Tittel, Nanette C Schloot, Elke Heitmann, Thorsten Otto

Diabetes Obes Metab· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-dependent prevalence of type 2 diabetes, cardiovascular risk profiles and use of diabetes drugs in Germany using health claims data.
Thorsten Otto, Joanna Diesing, Julia Borchert, Elke Heitmann, Nanette C Schloot

Diabetes Obes Metab· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
Bruno Guerci, Francesco Giorgino, Hélène Sapin, Kristina Boye, Jérémie Lebrec, Elke Heitmann

Diabetes Obes Metab· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
Luis-Emilio García-Pérez, Kristina S Boye, Myriam Rosilio, Heike Jung, Elke Heitmann

Diabetes Ther· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.
Kristina S Boye, Hélène Sapin, Luis-Emilio García-Pérez, Myriam Rosilio, Marco Orsini Federici, Elke Heitmann

Diabetes Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.
Martin Fuechtenbusch, Jens Aberle, Elke Heitmann, Claudia Nicolay, Heike Jung

Diabetes Obes Metab· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis